CAG方案治疗低增生性急性髓系白血病临床分析  被引量:1

Chemotherapy with CAG regimen to patients with hypoplastic acute myeloid leukemia

在线阅读下载全文

作  者:吕晓毅[1] 李艳[1] 何娟[1] 卢香兰[1] 柴静媛[1] 翟明[1] 

机构地区:[1]中国医科大学第一临床医院血液内科,沈阳110001

出  处:《山西医科大学学报》2006年第4期398-399,共2页Journal of Shanxi Medical University

摘  要:目的探讨CAG方案对低增生性急性髓系白血病治疗的疗效。方法分析低增生性急性髓系白血病住院患者52例,采用阿糖胞苷和阿克拉霉素联合粒细胞集落刺激因子(CAG)方案治疗并长期随访。结果CAG方案对低增生性急性髓系白血病的总有效率为79%,完全缓解(CR)率56%,部分缓解(PR)率28%,达CR者中生存期和无病生存期为14个月和7个月,PR和未缓解(NR)者中生存期分别为6个月和4个月。主要毒副作用是骨髓抑制,其他非血液学毒性表现轻微。结论CAG方案对低增生性急性髓系白血病患者有积极的治疗作用,副作用少,值得推广。Objective To investigate the efficacy of chemotherapy with CAG regimen to patients with hypoplastic acute myeloid leukemia (AML). Methods The patients with hypoplastic acute myeloid leukemia ( n = 52) were treated with CAG regimen and followed-up for a long-time. Results The total effective rate, complete remission (CR) and partial remission (PR) in patients with CAG regimen of hypoplastic AML were 79%, 56% and 28%, respectively. The median survival and disease-free survival of CR patients were 14 month and 7 month, and the median survival of PR and NR patients were 6 month and 4 month respectively. Bone marrow suppression was the common side effect, other non-hematologic toxicity was mild. Conclusion CAG regmen is effective to patients with hypoplastic AML and side effect is mild.

关 键 词:白血病 髓系 急性 药物疗法 CAG 

分 类 号:R733.71[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象